Staidson Beijing Biopharma (300204) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.046x

Based on the latest financial reports, Staidson Beijing Biopharma (300204) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-39.18 Million ≈ $-5.73 Million USD) by net assets (CN¥859.70 Million ≈ $125.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300204 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Staidson Beijing Biopharma - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Staidson Beijing Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Staidson Beijing Biopharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Staidson Beijing Biopharma ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Zhejiang Merit Interactive Network Technology Co Ltd Class A SHE:300766	-0.009x
Zhejiang Sanwei Rubber Item Co SHG:603033	0.002x
Ecovyst Inc NYSE:ECVT	0.029x
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	-0.129x
Perrigo Company PLC NYSE:PRGO	-0.045x
Sitio Royalties Corp. NYSE:STR	0.026x
BGF Retail Co Ltd KO:282330	0.268x
Zhongli Science and Technology Group Co Ltd SHE:002309	0.182x

Annual Cash Flow Conversion Efficiency for Staidson Beijing Biopharma (2007–2025)

The table below shows the annual cash flow conversion efficiency of Staidson Beijing Biopharma from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Staidson Beijing Biopharma market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥806.72 Million ≈ $118.05 Million	CN¥-125.68 Million ≈ $-18.39 Million	-0.156x	-124.28%
2024-12-31	CN¥916.76 Million ≈ $134.15 Million	CN¥-63.68 Million ≈ $-9.32 Million	-0.069x	+68.83%
2023-12-31	CN¥1.02 Billion ≈ $149.36 Million	CN¥-227.47 Million ≈ $-33.29 Million	-0.223x	-71.83%
2022-12-31	CN¥1.35 Billion ≈ $198.11 Million	CN¥-175.60 Million ≈ $-25.70 Million	-0.130x	-24.10%
2021-12-31	CN¥1.55 Billion ≈ $226.92 Million	CN¥-162.07 Million ≈ $-23.72 Million	-0.105x	-44.78%
2020-12-31	CN¥1.59 Billion ≈ $232.30 Million	CN¥-114.60 Million ≈ $-16.77 Million	-0.072x	-366.21%
2019-12-31	CN¥1.64 Billion ≈ $239.29 Million	CN¥44.34 Million ≈ $6.49 Million	0.027x	-59.63%
2018-12-31	CN¥2.46 Billion ≈ $359.66 Million	CN¥165.08 Million ≈ $24.16 Million	0.067x	-45.77%
2017-12-31	CN¥2.21 Billion ≈ $323.30 Million	CN¥273.64 Million ≈ $40.04 Million	0.124x	+11.78%
2016-12-31	CN¥1.92 Billion ≈ $280.70 Million	CN¥212.55 Million ≈ $31.10 Million	0.111x	-19.24%
2015-12-31	CN¥1.68 Billion ≈ $246.39 Million	CN¥231.01 Million ≈ $33.80 Million	0.137x	+0.44%
2014-12-31	CN¥1.51 Billion ≈ $221.60 Million	CN¥206.85 Million ≈ $30.27 Million	0.137x	+61.17%
2013-12-31	CN¥1.31 Billion ≈ $192.28 Million	CN¥111.36 Million ≈ $16.30 Million	0.085x	+16.61%
2012-12-31	CN¥1.24 Billion ≈ $181.57 Million	CN¥90.19 Million ≈ $13.20 Million	0.073x	-7.94%
2011-12-31	CN¥1.10 Billion ≈ $161.27 Million	CN¥87.01 Million ≈ $12.73 Million	0.079x	-79.46%
2010-12-31	CN¥166.23 Million ≈ $24.32 Million	CN¥63.91 Million ≈ $9.35 Million	0.384x	+8.64%
2009-12-31	CN¥119.72 Million ≈ $17.52 Million	CN¥42.37 Million ≈ $6.20 Million	0.354x	+36.99%
2008-12-31	CN¥62.82 Million ≈ $9.19 Million	CN¥16.23 Million ≈ $2.37 Million	0.258x	+61.81%
2007-12-31	CN¥33.87 Million ≈ $4.96 Million	CN¥5.41 Million ≈ $791.30K	0.160x	--

About Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.41 Billion

CN¥9.61 Billion CNY

Market Cap Rank

#7651 Global

#1789 in China

Share Price

CN¥20.11

Change (1 day)

-2.19%

52-Week Range

CN¥20.11 - CN¥61.00

All Time High

CN¥61.00